+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 19Years +
MALE
ID06334120

Observational Safety Study of Darolutamide in Korean Men with Non-Metastatic Castration-Resistant or Metastatic Hormone-Sensitive Prostate Cancer

Led by Bayer · Updated on 2026-10-20

600

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing men in Korea who have either non-metastatic castration-resistant prostate cancer nmCRPC or metastatic hormone-sensitive prostate cancer mHSPC. These are types of prostate cancer where nmCRPC has not spread and does not respond to lowering testosterone, while mHSPC has spread and can be treated by lowering testosterone. The study focuses on assessing the safety of the drug darolutamide in these patients, which is already approved and prescribed by doctors. Darolutamide works by blocking hormones from attaching to androgen receptors in prostate cells, which may slow cancer growth. Participants in this study are men already prescribed darolutamide by their doctors as part of routine care. The dose and treatment length are decided by the treating physician following local guidelines. The study collects data from medical records over one year, including information on adverse events and how the drug is working. This post-marketing surveillance aims to better understand darolutamides safety in Korean patients with these prostate cancer types. During the one-year participation, patients visit their doctors every 2 to 4 months as part of normal care. At these visits, scans and blood tests are done to monitor the cancer, and patients report any medications they take and adverse events experienced. Researchers track the number, severity, and outcomes of adverse events and adverse drug reactions for up to 30 days after treatment ends. They also observe measures related to cancer progression and survival during this period. The entire study will run for about six years.

CONDITIONS

Brief Title

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Research Team

B

Bayer Clinical Trials Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here